Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer

International Journal of Pancreatology

Volumn 29, Issue 1, 2001, Pages 9-18

  Crane, C H ^a   Janjan, N A ^a   Evans, D B ^a   Wolff, R A ^a   Ballo, M T ^a   Milas, L ^a   Mason, K ^a   Charnsangavej, C ^a   Pisters, P W T ^a   Lee, J E ^a   Lenzi, R ^a   Vauthey, J N ^a   Wong, A ^a   Phan, T ^a   Nguyen, Q ^a   Abbruzzese, J L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gemcitabine; Pancreatic neoplasms; Radiotherapy; Unresectable

Indexed keywords

GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIAGNOSTIC IMAGING; DRUG SAFETY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH ULCER; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT FAILURE;

ADENOCARCINOMA; ADULT; AGED; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 0034825882     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/IJGC:29:1:09     Document Type: Article

References (37)

1. Enhancement of tumor radioresponse in vivo by gemcitabine
2. Maximizing therapeutic gain with gencitabine and franctionated radiation
3. Radioenhancement by gemcitabine with accelerated fractionated radiotherapy in a human tumor xenograft model
4. Gemcitabine-mediated radiosensitization
5. Gemcitabine radiosensitizes human pancreas cancer cells
6. A phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer
7. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma
8. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
9. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
10. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
11. Gemcitabine: Effective palliative therapy for pancreas cancer patients failing 5-FU
12. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma
13. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group
14. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally resectable pancreatic carcinoma
15. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
16. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
17. Combined modality treatment of localized unresectable adehocarcinoma of the pancreas
18. Enhancement of tumor radioresponse in vivo by gemcitabine
19. Identification of a window of therapeutic opportunity for the combination of gemcitabine and radiation
20. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
21. Surgical resection following concurrent gemcitabine/radiation therapy in patients with previously unresectable pancreatic cancer
22. Phase II study of gemcitabine combined with radiation therapy in localized, unresectable pancreatic cancer
23. A phase I trial of simultaneous gemcitabine/cisplatin and radiotherapy for patients with locally advanced pancreatic cancer
24. Radiochemotherapy including gemcitabine and F-fluorouracil for treatment of locally advanced pancreatic cancer
25. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer
26. Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer
27. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas
28. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer
29. Long-term results of combined modality - Treatment with I-125 implantation for carcinoma of the pancreas
30. Intraoperative radiation therapy for patients with pancreatic carcinoma
31. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas: Treatment variables and survival duration
32. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
33. Phase I trial of gemcitabine and escalating dose radiation therapy in patients with pancreatic carcinoma
34. Concurrent gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: A phase I/II study
35. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
36. Gemcitabine plus radiotherapy in stage II-III pancreatic cancer: A phase I trial
37. A phase I trial of preoperative gemcitabine and radiotherapy followed by postoperative gemcitabine for patients with localized, resectable, pancreatic adenocarcinoma